News | April 28, 2009

PET Scanning Guide Helps Doctors Treat Variety of Cancers

April 28, 2009 - Experts have compiled a comprehensive overview of the literature regarding the usefulness of PET imaging for the treatment of several cancers, "Personalizing Cancer Therapy with FDG PET: From RECIST to PERCIST," providing a compilation of results of therapeutic regimens across a broad range of cancers published as a supplement to The Journal of Nuclear Medicine

The reference tool presents the most up-to-date information about the use of fluorodeoxyglucose and positron emission tomography (FDG-PET) for monitoring therapy and treatment of many different cancers. Internationally recognized PET imaging specialists and oncologists contributed to and developed this new supplement.

FDG-PET is a noninvasive, painless molecular imaging technology that allows physicians to determine how organs and tissues inside the body are functioning on a molecular and cellular level. In the past, collecting information about tumor response in a structured and meaningful format was difficult. As a result, generally accepted criteria for response assessment in solid tumors did not exist. Because each patient is unique, oncologists have no way of accurately predicting which patient will benefit from a specific therapy.

Those involved in the production of the new supplement believe that the international guidelines and criteria for response assessment using PET in solid tumors provided by the new periodical may notably alter cancer treatment and prognosis.

“The literature in this publication suggests that FDG-PET could play a significant role in personalizing the treatment of malignant tumors,” said Wolfgang Weber, M.D., editor of the supplement and medical director with the division of nuclear medicine at the Albert-Ludwigs University in Freiburg, Germany. “It could positively impact patient care by providing access to critical imaging procedures to ensure that patients get the right treatment early on in their cancer.”

Most anticancer drugs are effective only in subgroups of patients, and many of the various techniques developed to monitor tumor response to these drugs have proven to be inadequate. “FDG PET imaging, on the other hand, has been shown to improve response assessment in several tumor types, such as lymphoma, and a variety of single-center studies have shown that FDG PET may provide earlier or more accurate assessment of tumor response in other types of cancer.

Because the supplement aims to present a careful discussion of the available literature and provide guidance for treatment monitoring with FDG-PET, researchers involved in a wide range of cancer studies were given templates to use for reporting purposes to ensure that data was collected in a meaningful way. The researchers then methodically summarized strengths and weaknesses of various approaches for predicting or monitoring tumor response, and described common methodological differences between individual studies and their effects on the reported diagnostic accuracy of FDG-PET.

“Previously, researchers used different criteria and their results were inconsistent,” explained Weber. “The tabulated format we required for this publication provided the necessary structure to gather data and made it possible to compare results from different studies, making it easier for doctors to find valuable information in a uniformly structured and centralized location.”

Source: The Journal of Nuclear Medicine

For more information: www.snm.org

Related Content

Axumin PET Agent Added to NCCN Guidelines for Suspected Recurrent Prostate Cancer
News | PET Imaging | February 21, 2018
Blue Earth Diagnostics announced that Axumin (fluciclovine F 18) injection has been added to the National Comprehensive...
PSMA PET-CT Clearly Differentiates Prostate Cancer from Benign Tissue

68Ga-PSMA PET/CT images showing multifocal PCA in peripheral zone with GS of 5 1 5 5 10. (A and C) Axial PET images. (B and D) Fused PET/CT images. SUVmax of lesion in B was 84.3 and that of lesion in D was 5.7. IRS was 3, and 80% of cells were stained. Credit: Senior author V Prasad, Charité Universitätsmedizin Berlin, Berlin, Germany.

News | PET-CT | February 05, 2018
February 5, 2018 — Using nuclear medicine...
PET Tracer Measures Damage From Multiple Sclerosis in Mouse Models
News | PET Imaging | January 24, 2018
January 24, 2018 — The loss or damage of myelin, a cellular sheath that surrounds and insulates nerves, is the hallma
Novel PET Tracer Clearly Identifies and Tracks Bacterial Lung Infection

Representative PET/CT images of 18F-FDS and 18F-FDG in inflamed mice. Mice were inoculated with dead K. pneumoniae (10^8 CFU/mL). Imaging was performed for days 1, 2, 3 and 4 using 18F-FDG and 18F-FDS. CT images showed clear inflammation on day 2 and day 3 with corresponding high 18F-FDG uptake on PET. No significant uptake of 18F-FDS was detected for any of those 4 days. Credit: J Li et al., University of Louisville School of Medicine, Louisville, Ky.

News | PET-CT | January 22, 2018
January 22, 2018 — Researchers at the University of Louisville, Kentucky, have demonstrated that a new...
PET Tracer Gauges Effectiveness of Promising Alzheimer's Treatment

Longitudinal PET imaging with 18F-AV45. PET imaging shows the average 18F-AV45 uptake per animal group at 8 and 13 months of age. A significant interaction of genotype treatment was observed in the cortex (p = 0.0248), hippocampus (p = 0.0071) and thalamus (p = 0.0084), indicating reduced [18F]-AV45 uptake in BACE1 inhibited transgenic mice. Credit: MICA, University of Antwerp, Belgium.

News | Radiopharmaceuticals and Tracers | December 28, 2017
In the December featured basic science article in The Journal of Nuclear Medicine, Belgian researchers report on the...
Michael J. Fox Foundation and Tau Consortium Developing PET Tracers for Neurodegenerative Disease
News | Radiopharmaceuticals and Tracers | October 27, 2017
The Michael J. Fox Foundation for Parkinson's Research (MJFF) and the Tau Consortium announced a funding partnership to...
SNMMI Publishes New FDG PET/CT Appropriate Use Criteria
News | PET-CT | October 25, 2017
The Society of Nuclear Medicine and Molecular Imaging (SNMMI) has published appropriate use criteria (AUC) for FDG PET/...
Majority of Recurrent Prostate Cancer Patients' Treatment Plan Changed Following Fluciclovine 18F PET/CT
News | Prostate Cancer | October 04, 2017
Blue Earth Diagnostics recently announced the results of a pre-planned interim analysis from an investigational...
Toshiba Highlights Latest CT Advancements at RSNA 2017
News | Computed Tomography (CT) | September 18, 2017
Toshiba Medical announced that it will display several new enhancements to its existing computed tomography (CT)...
Double Targeting Ligands to Identify and Treat Prostate Cancer

The mice were imaged with small-animal PET/CT using 124I-RPS-027 (7.4 MBq [200 μCi]). Credit: JM Kelly et al., Department of Radiology, Weill Cornell Medicine, New York, NY

News | Prostate Cancer | September 14, 2017
Researchers have demonstrated a new, effective way to precisely identify and localize prostate cancer tumors while...
Overlay Init